Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

[1]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[2]  W. Scheithauer,et al.  Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. , 2017, European journal of cancer.

[3]  A. Mattia,et al.  A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome , 2017, Modern Pathology.

[4]  H. Sakamoto,et al.  Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. , 2017, Anticancer research.

[5]  A. Duval,et al.  Immunotherapy and patients treated for cancer with microsatellite instability. , 2017, Bulletin du cancer.

[6]  J. Taïeb,et al.  Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. , 2016, Journal of the National Cancer Institute.

[7]  B. Vogelstein,et al.  Programmed death-1 blockade in mismatch repair deficient colorectal cancer. , 2016 .

[8]  P. Laurent-Puig,et al.  Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. , 2016, JAMA oncology.

[9]  B. Vogelstein,et al.  PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. , 2016 .

[10]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[12]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Gruber,et al.  Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Evans,et al.  Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC) , 2014, Journal of Medical Genetics.

[15]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[16]  Randall W Burt,et al.  Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. , 2014, Diseases of the colon and rectum.

[17]  P. Gibbs,et al.  Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Balmaña,et al.  Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Sabine Tejpar,et al.  Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[21]  P. Gibbs,et al.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer , 2011, Cancer.

[22]  R. Labianca,et al.  DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.

[23]  R. Labianca,et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Ligtenberg,et al.  Deficient mismatch repair system in patients with sporadic advanced colorectal cancer , 2009, British Journal of Cancer.

[26]  D. Sargent,et al.  Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer , 2008, Clinical Cancer Research.

[27]  J. Cucherousset,et al.  Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. , 2007, Anticancer research.

[28]  C. Koebnick,et al.  Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. , 2003, Anticancer research.

[29]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.